Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
Hypoglycaemia is a condition usually experienced by people with diabetes when the level of sugar in the blood falls to a very low level. Hypoglycaemia is often caused by the medication people with diabetes take but it can also be caused by exercise, diet and having other conditions as well as diabetes. Hypoglycaemia causes symptoms such as tiredness and dizziness but can also cause very serious symptoms such as loss of consciousness and can even be fatal if it is not treated. In some parts of the UK, ambulance staff who attend patients with hypoglycaemia can refer them to a new care pathway aimed at preventing further episodes of hypoglycaemia. As part of this care pathway, ambulance staff give the patient’s details to a nurse who is specially trained in helping people with diabetes. This nurse then contacts the patient by phone to talk about why the person had hypoglycaemia and how they can avoid it in the future. If necessary, the nurse may arrange an out-patient appointment or request that the patients’ medication is changed. There have been small studies of this care pathway to see whether it is effective at preventing further episodes of hypoglycaemia. Although the results have been promising we need to collect more data to see if the care pathway can be set up in new areas and prevent future episodes of hypoglycaemia and improve overall outcomes for patients.

Who can participate?
Patients aged 18 or older living in Northamptonshire or Lincolnshire, assessed by a paramedic as hypoglycaemic.

What does the study involve?
Ambulance staff either refer patients to the new care pathway or send the patient’s details to their GP. This is determined randomly. Patients allocated to the new care pathway receive help and advice from a diabetes specialist nurse who may discuss the cause of the hypoglycaemia and how it can be prevented in the future, in addition to an advice leaflet. The nurse also conducts a review of the patients' current medications to establish if any changes are required to help prevent future episodes. The other patients still receive an advice leaflet but are asked to visit their GP to discuss their hypoglycaemia. Referred patients are followed-up four weeks later. This involves sending them an invitation letter and information leaflet along with a consent form and a questionnaire to complete. Patients who consent to take part are followed up 12 months later. This involves contacting the patient’s general practice to obtain relevant information about the patient, which is agreed to when the patient consents to join the study.

What are the possible benefits and risks of participating?
Participants in both groups will receive help and advice about hypoglycaemia. As the intervention does not include changes to the way in which patients with hypoglycaemia are treated there are no anticipated risks from the intervention per se. However, if participants consent to the study their GP will be made aware that they have been treated by a paramedic for a hypoglycaemic event. This may have implications for their ability to drive as the DVLA would normally be informed of the episode of hypoglycaemia.

Where is the study run from?
The study is taking place in Northamptonshire, where the ambulance service and the diabetes care service are both involved.

When is the study starting and how long is it expected to run for?
January 2015 to April 2018.

Who is funding the study?
National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care East Midlands (UK).

Who is the main contact?
Dr Andy Willis

Trial website

Contact information



Primary contact

Dr Andy Willis


Contact details

Leicester Diabetes Centre
Gwendolen Road
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number

UNOLE 0550

Study information

Scientific title

Innovative hypoglycaemia pathway for self-care at home and admission avoidance: a partnership approach with a regional ambulance trust


Study hypothesis

Patients randomised to the intervention arm of the study (intervention from a diabetes nurse) will have a higher rate of evidence of discussion of the hypo and/or change in medication documented in the participants' medical notes when compared to participants randomised to the control arm (GP referral).

Ethics approval

East Midlands - Nottingham 1 committee, 19/01/2016, REC ref: 15/EM/0538

Study design

Multicentre randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet.


Prevention of hypoglycaemia in people with diabetes


Patients are randomised to the intervention arm (intervention from a diabetes nurse) or the control arm (GP referral).

The intervention involves ambulance staff from East Midlands Ambulance Service attending the call-out and Diabetes Specialist Nurses working for the Integrated Care Diabetes Service in Leicester. The ambulance staff gives the patient a “Hypos can Strike Twice” information booklet. The booklet includes information on what a ‘hypo’ is, their prevention and treatment as well as advice on driving. The booklet explains that the patient will be contacted by phone within two working days, by a DSN who will discuss the episode of hypoglycaemia, offer advice and suggest treatment changes (if required) in an attempt to prevent future hypoglycaemic episodes. If the DSN is unable to contact the patient by telephone a letter is sent offering them a face-to-face appointment. The general practitioner (GP) is informed following all telephone calls and consultations or if the patient refuses an appointment.

Intervention type



Drug names

Primary outcome measure

Documented evidence in the patient’s notes (practice notes or those maintained by DSNs) that the hypoglycaemic episode was discussed (within 4 weeks of the call-out) during a telephone consultation or a face-to-face consultation with a Health Care Professional (HCP), and that advice was given and/or changes made to their medication

Secondary outcome measures

1. Patient’s satisfaction with the treatment they have received (Diabetes Treatment Satisfaction Questionnaire (Bradley, 1994)) 4 weeks after consent
2. Patient’s knowledge of DVLA driving regulations relating to hypoglycaemia (unvalidated questionnaire) 4 weeks after consent
3. Patient’s fear of hypoglycaemia, Fear of Hypoglycaemia Scale (Cox et al., 1987) 4 weeks after consent
4. Patient’s quality of life EQ5D (The EuroQol Group, 1990) 4 weeks after consent
5. Rates of CVD and CVD-related mortality (rates of all-cause mortality) extracted from patients medical notes at 12 months after consent
6. Rate of hypoglycaemic episodes requiring repeat ambulance attendance (recorded by ambulance service) collected at 12 months after consent
7. Rate of hypoglycaemic episodes requiring repeat ambulance attendance and conveyance to hospital (including information on whether or not admitted) (recorded by ambulance service) collected at 12 months after consent

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Willing and able to give informed consent
2. Age 18 years and older
3. Able to speak and read English
4. Paramedic assessment of a hypoglycaemic event on the basis of blood glucose reading of <4.0 mmol/l
5. Lives in Northamptonshire or Lincolnshire
6. Responsible for their own care and/or medication

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Unwilling or not able to give informed consent
2. Aged under 18 years
3. Not able to speak and read English
4. Lives outside Northamptonshire and Lincolnshire
5. Not responsible for their own care and/or their medication
6. Previously referred to the present study
7. Admitted to hospital for more than 2 days
8. Registered with a GP outside of the Northamptonshire or Lincolnshire CCGs (i.e., Nene and Corby, West Lincolnshire, East Lincolnshire, South West Lincolnshire and South Lincolnshire, respectively)

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Leicester Diabetes Centre
Leicester General Hospital Gwendolen Road
United Kingdom

Trial participating centre

East Midlands Ambulance Service NHS Trust
East Division HQ Cross O’Cliff Court Bracebridge Heath
United Kingdom

Sponsor information


University of Leicester (UK)

Sponsor details

Academic Department
Leicester General Hospital
Gwendolen Road
United Kingdom

Sponsor type




Funder type


Funder name

National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care East Midlands (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date


Participant level data

Not expected to be available

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

23/10/2017: Internal review. 05/04/2016: Ethics approval information added.